Achaogen Inc (AKAO) PT Raised to $28.00

Achaogen Inc (NASDAQ:AKAO) had its target price raised by Stifel Nicolaus from $27.00 to $28.00 in a report released on Wednesday morning. They currently have a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Achaogen from a buy rating to a hold rating in a report on Wednesday, March 8th. Wedbush raised their price objective on shares of Achaogen from $23.00 to $28.00 and gave the company an outperform rating in a report on Monday, March 6th. Needham & Company LLC raised their price objective on shares of Achaogen from $19.00 to $29.00 and gave the company a buy rating in a report on Thursday, March 2nd. Vetr lowered shares of Achaogen from a strong-buy rating to a buy rating and set a $25.80 price objective for the company. in a report on Wednesday, February 22nd. Finally, Guggenheim reiterated a buy rating and issued a $30.00 price objective on shares of Achaogen in a report on Tuesday, January 24th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $25.98.

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) opened at 22.64 on Wednesday. Achaogen has a one year low of $2.59 and a one year high of $27.79. The firm’s market cap is $648.70 million. The company’s 50-day moving average is $21.99 and its 200-day moving average is $11.44.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Tuesday, March 14th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by $0.55. Achaogen had a negative net margin of 147.80% and a negative return on equity of 143.44%. The company earned $10.73 million during the quarter, compared to analyst estimates of $13.33 million. During the same quarter in the previous year, the business posted ($0.61) earnings per share. The company’s revenue for the quarter was up 130.3% on a year-over-year basis. On average, analysts forecast that Achaogen will post ($2.25) earnings per share for the current fiscal year.

Your IP Address:

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Artal Group S.A. purchased a new position in Achaogen during the fourth quarter valued at about $781,000. Opaleye Management Inc. purchased a new position in Achaogen during the fourth quarter valued at about $1,041,000. Paulson & CO. Inc. purchased a new position in Achaogen during the fourth quarter valued at about $944,000. Ellington Management Group LLC purchased a new position in Achaogen during the fourth quarter valued at about $391,000. Finally, Tudor Investment Corp Et Al purchased a new position in Achaogen during the fourth quarter valued at about $651,000. Hedge funds and other institutional investors own 44.47% of the company’s stock.

Achaogen Company Profile

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

5 Day Chart for NASDAQ:AKAO

Receive News & Ratings for Achaogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.